Skip to main content
. 2018 Mar 13;7(4):e1397248. doi: 10.1080/2162402X.2017.1397248

Figure 3.

Figure 3.

Anti-CD47 treatment by monoclonal antibody delays tumorigenesis in immunocompetent transgenic HNSCC mouse models. Representative immunohistochemical staining (A), western blot with GAPDH as a loading control of CD47 (B) and immunofluorescence staining for CD47 (red immunofluorescene), CK14 (green) and nucleus (blue) (C) in Tgfbr1/Pten 2cKO mice HNSCC compared with wild-type tongue. (D) Tgfbr1/Pten 2cKO mice bearing carcinoma by tamoxifen were treated with the CD47 antibody (αCD47) intraperitoneally (i.p) every other day for 28 days or isotype control treated (n = 5 mice respectively). (E) Tumor burden and representative photos of mice with head and neck tumor (right panel) after treatment with αCD47 or isotype IgG in day 18 and day 32 after tamoxifen gavage. Data presented as mean ± SEM.